Feature Review for Cancer Therapy: 2nd Edition

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 1563

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 3, Rokietnicka Street, 60-806 Poznań, Poland
Interests: head and neck cancer; hepatocellular cancer; pancreatic cancer; CNS cancer; colorectal cancer; targeted therapy; Wnt signaling pathway; metabolism of cancer cells social media account
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 3, Rokietnicka Street, 60-806 Poznań, Poland
Interests: head and neck cancer; epigenetics; CNS cancer; colorectal cancer; targeted therapy; Wnt signaling pathway; metabolism of cancer cells; metronomic therapy; biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of the Special Issue “Feature Review for Cancer Therapy”, available at: https://www.mdpi.com/journal/cancers/special_issues/30GWB72QHW.

The molecular diversity in cancers is reflected by the lack of universal treatment options. However, the understanding of the molecular and cellular hallmarks of cancer, presented by Hanahan and Weinberg, has contributed to significant progress in oncological therapies. It has allowed researchers to improve the clinical efficacy of classical cytostatic drugs but has also resulted in the development of new targeted therapeutics. Additionally, our growing comprehension of the role of stem-like cancer cells holds promise for a more robust eradication of tumors by targeting the subpopulation of cells responsible for self-renewal and chemo/radio-resistance. Moreover, the growing understanding of the cross-talk between various cell types that are present in the tumor microenvironment translates into current immunomodulatory and other therapies.

This Special Issue aims to address the recent findings of research devoted to the improvement in oncological therapies, both at the experimental and clinical levels.

Potential topics include, but are not limited to:

  • Current standard treatment of cancer;
  • Current and potential targeted therapy of cancer;
  • Combinations of different therapeutic options;
  • Biomarkers for the improvement in therapy;
  • Natural compounds and their derivatives in cancer therapy;
  • Drug repurposing for cancer therapy;
  • Nanomaterials in cancer treatment;
  • Perspectives for the de-escalation of anticancer therapy.

Dr. Robert Kleszcz
Dr. Jarosław Paluszczak
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Only review articles are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer therapy
  • chemotherapy
  • targeted therapy
  • cancer co-treatment
  • biomarkers
  • natural compounds
  • drug-repurposing
  • nanomaterials

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

43 pages, 2337 KB  
Review
The Targeted Inhibition of Histone Lysine Demethylases as a Novel Promising Anti-Cancer Therapeutic Strategy—An Update on Recent Evidence
by Jarosław Paluszczak and Robert Kleszcz
Cancers 2025, 17(17), 2798; https://doi.org/10.3390/cancers17172798 - 27 Aug 2025
Abstract
A growing body of evidence confirms that non-mutational epigenetic reprogramming constitutes an important hallmark of cancer, contributing to the heterogeneity and phenotypic plasticity observed in cancers. Among the many epigenetic modulators, histone lysine demethylases (KDMs) have emerged as promising targets for pharmacological inhibition [...] Read more.
A growing body of evidence confirms that non-mutational epigenetic reprogramming constitutes an important hallmark of cancer, contributing to the heterogeneity and phenotypic plasticity observed in cancers. Among the many epigenetic modulators, histone lysine demethylases (KDMs) have emerged as promising targets for pharmacological inhibition in cancer treatment. KDMs were found to be frequently overexpressed and/or hyperactivated in cancer cells, and their inhibition was shown to result in the inhibition of cancer cell growth both in vitro and in vivo. The inhibition of Lysine-specific histone demethylase 1A (LSD1), KDM3, KDM4, KDM5, and KDM6 may affect cell survival, proliferation, motility, and apoptosis induction. Importantly, KDM inhibitors can be used as modulators of anti-cancer immune response and sensitivity to radiation and chemotherapy. This narrative review aims to present the most recent evidence documenting the anti-cancer potential of KDM inhibitors. Full article
(This article belongs to the Special Issue Feature Review for Cancer Therapy: 2nd Edition)
Show Figures

Graphical abstract

25 pages, 1207 KB  
Review
The Era of Precision Medicine: Advancing Treatment Paradigms for Small Cell Lung Cancer
by Derek A. Corica, Scott D. Bell, Lei Zhao, Nicholas J. Lawler, McKade A. Poirier, Peyton J. Miller, Mark R. Wakefield and Yujiang Fang
Cancers 2025, 17(11), 1847; https://doi.org/10.3390/cancers17111847 - 31 May 2025
Viewed by 1290
Abstract
Small cell lung cancer (SCLC) remains a challenge prognostically. A clinically silent early stage and predilection for early metastasis leads to over half of patients presenting with metastatic disease at the time of diagnosis. Akin to many other cancers, once SCLC metastasizes, current [...] Read more.
Small cell lung cancer (SCLC) remains a challenge prognostically. A clinically silent early stage and predilection for early metastasis leads to over half of patients presenting with metastatic disease at the time of diagnosis. Akin to many other cancers, once SCLC metastasizes, current therapies begin to lose their effectiveness. The future of SCLC rests in innovative treatments aimed at improving patient outcomes. Chemotherapy and radiation remain the backbone treatment for SCLC. Most patients diagnosed with SCLC begin treatment with combination chemotherapy consisting of a platinum analog and topoisomerase inhibitor with or without concurrent radiation. Disease progression or recurrence warrants new treatment approaches. New chemotherapy combinations and advances in radiation precision offer patients novel approaches using the same backbone of treatment used in many other cancers. The introduction of newer therapeutic approaches, such as immune checkpoint inhibitors, small molecule targeted therapies, bispecific antibodies, and antibody–drug conjugates offer a bright future for patients with SCLC who fail first-line therapy. This review will focus on advancing treatment paradigms for SCLC in the era of precision medicine. Such a study might be helpful for pulmonologists and oncologists to manage precisely patients with SCLC. Full article
(This article belongs to the Special Issue Feature Review for Cancer Therapy: 2nd Edition)
Show Figures

Figure 1

Back to TopTop